Exelixis | EXEL

Stock Price
37.88
Daily Change
0.50 1.34%
Monthly
0.45%
Yearly
50.62%
Q3 Forecast
37.57

Peers Price Chg Day Year Date
Takeda 4,574.00 33.00 0.73% 7.09% Sep/05
Eisai 5,137.00 125.00 2.49% -11.57% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Sanofi 46.50 1.18 2.60% -19.47% Sep/05
Xencor 8.55 0.18 2.15% -47.16% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05
US400 3297 16.31 0.50% 12.16% Sep/05

Exelixis traded at $37.88 this Friday September 5th, increasing $0.50 or 1.34 percent since the previous trading session. Looking back, over the last four weeks, Exelixis gained 0.45 percent. Over the last 12 months, its price rose by 50.62 percent. Looking ahead, we forecast Exelixis to be priced at 37.57 by the end of this quarter and at 36.64 in one year, according to Trading Economics global macro models projections and analysts expectations.

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.